These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

390 related items for PubMed ID: 15715478

  • 1. Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity.
    Tsou HR, Overbeek-Klumpers EG, Hallett WA, Reich MF, Floyd MB, Johnson BD, Michalak RS, Nilakantan R, Discafani C, Golas J, Rabindran SK, Shen R, Shi X, Wang YF, Upeslacis J, Wissner A.
    J Med Chem; 2005 Feb 24; 48(4):1107-31. PubMed ID: 15715478
    [Abstract] [Full Text] [Related]

  • 2. Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2).
    Wissner A, Overbeek E, Reich MF, Floyd MB, Johnson BD, Mamuya N, Rosfjord EC, Discafani C, Davis R, Shi X, Rabindran SK, Gruber BC, Ye F, Hallett WA, Nilakantan R, Shen R, Wang YF, Greenberger LM, Tsou HR.
    J Med Chem; 2003 Jan 02; 46(1):49-63. PubMed ID: 12502359
    [Abstract] [Full Text] [Related]

  • 3. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase.
    Rabindran SK, Discafani CM, Rosfjord EC, Baxter M, Floyd MB, Golas J, Hallett WA, Johnson BD, Nilakantan R, Overbeek E, Reich MF, Shen R, Shi X, Tsou HR, Wang YF, Wissner A.
    Cancer Res; 2004 Jun 01; 64(11):3958-65. PubMed ID: 15173008
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Synthesis and antitumor evaluation of novel 5-substituted-4-hydroxy-8-nitroquinazolines as EGFR signaling-targeted inhibitors.
    Jin Y, Li HY, Lin LP, Tan J, Ding J, Luo X, Long YQ.
    Bioorg Med Chem; 2005 Oct 01; 13(19):5613-22. PubMed ID: 15993078
    [Abstract] [Full Text] [Related]

  • 11. Synthesis and antiproliferative activity of tyrphostins containing quinoline moieties.
    Brunton VG, Lear MJ, McKeown P, Robins DJ, Workman P.
    Anticancer Drug Des; 1996 Sep 01; 11(6):463-83. PubMed ID: 8836111
    [Abstract] [Full Text] [Related]

  • 12. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer.
    Rusnak DW, Affleck K, Cockerill SG, Stubberfield C, Harris R, Page M, Smith KJ, Guntrip SB, Carter MC, Shaw RJ, Jowett A, Stables J, Topley P, Wood ER, Brignola PS, Kadwell SH, Reep BR, Mullin RJ, Alligood KJ, Keith BR, Crosby RM, Murray DM, Knight WB, Gilmer TM, Lackey K.
    Cancer Res; 2001 Oct 01; 61(19):7196-203. PubMed ID: 11585755
    [Abstract] [Full Text] [Related]

  • 13. Synthesis and structure-activity relationships of N-benzyl-N-(X-2-hydroxybenzyl)-N'-phenylureas and thioureas as antitumor agents.
    Li HQ, Yan T, Yang Y, Shi L, Zhou CF, Zhu HL.
    Bioorg Med Chem; 2010 Jan 01; 18(1):305-13. PubMed ID: 19914837
    [Abstract] [Full Text] [Related]

  • 14. Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.
    Thompson AM, Murray DK, Elliott WL, Fry DW, Nelson JA, Showalter HD, Roberts BJ, Vincent PW, Denny WA.
    J Med Chem; 1997 Nov 21; 40(24):3915-25. PubMed ID: 9397172
    [Abstract] [Full Text] [Related]

  • 15. Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinases.
    Xu G, Searle LL, Hughes TV, Beck AK, Connolly PJ, Abad MC, Neeper MP, Struble GT, Springer BA, Emanuel SL, Gruninger RH, Pandey N, Adams M, Moreno-Mazza S, Fuentes-Pesquera AR, Middleton SA, Greenberger LM.
    Bioorg Med Chem Lett; 2008 Jun 15; 18(12):3495-9. PubMed ID: 18508264
    [Abstract] [Full Text] [Related]

  • 16. Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors.
    Emanuel SL, Hughes TV, Adams M, Rugg CA, Fuentes-Pesquera A, Connolly PJ, Pandey N, Moreno-Mazza S, Butler J, Borowski V, Middleton SA, Gruninger RH, Story JR, Napier C, Hollister B, Greenberger LM.
    Mol Pharmacol; 2008 Feb 15; 73(2):338-48. PubMed ID: 17975007
    [Abstract] [Full Text] [Related]

  • 17. 4-Anilino-6,7-dialkoxyquinoline-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilino-6,7-dialkoxyquinazoline inhibitors.
    Wissner A, Berger DM, Boschelli DH, Floyd MB, Greenberger LM, Gruber BC, Johnson BD, Mamuya N, Nilakantan R, Reich MF, Shen R, Tsou HR, Upeslacis E, Wang YF, Wu B, Ye F, Zhang N.
    J Med Chem; 2000 Aug 24; 43(17):3244-56. PubMed ID: 10966743
    [Abstract] [Full Text] [Related]

  • 18. Synthesis, biological evaluation and molecular docking studies of amide-coupled benzoic nitrogen mustard derivatives as potential antitumor agents.
    Zheng QZ, Zhang F, Cheng K, Yang Y, Chen Y, Qian Y, Zhang HJ, Li HQ, Zhou CF, An SQ, Jiao QC, Zhu HL.
    Bioorg Med Chem; 2010 Jan 15; 18(2):880-6. PubMed ID: 20005116
    [Abstract] [Full Text] [Related]

  • 19. Discovery of novel small-molecule inhibitors of human epidermal growth factor receptor-2: combined ligand and target-based approach.
    Gundla R, Kazemi R, Sanam R, Muttineni R, Sarma JA, Dayam R, Neamati N.
    J Med Chem; 2008 Jun 26; 51(12):3367-77. PubMed ID: 18500794
    [Abstract] [Full Text] [Related]

  • 20. Receptor-guided alignment-based comparative 3D-QSAR studies of benzylidene malonitrile tyrphostins as EGFR and HER-2 kinase inhibitors.
    Kamath S, Buolamwini JK.
    J Med Chem; 2003 Oct 23; 46(22):4657-68. PubMed ID: 14561085
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.